Recent Updates
Recently added Catalysts
ECOR Positive Sentiment

electroCore to Participate in the 25th Annual Needham Virtual Healthcare Conference

Key Takeaway: electroCore, Inc. will participate in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. Interim President Joshua Lev will present at 2:15 pm ET and engage in one-on-one meetings with investors. This event highlights the company's focus on advancing bioelectronic technologies for health improvement.
Price reaction · baseline $6.71 (2026-04-07 close) · hit after-hours · clean, no other ECOR news in the window
day 0 close · peak
-7.5%
day 1
-0.9%
day 3
-6.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a notable healthcare conference
  • Opportunity for one-on-one investor meetings
  • Showcases company's commitment to innovation in bioelectronic medicine

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~6 mo
High dilution risk
Lead asset
GammaCore
Phase 2 · Chronic Cluster Headache

Full Press Release Details

ROCKAWAY, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Needham Virtual Healthcare Conference taking place virtually on April 15, 2026.
Joshua Lev, Interim President and Chief Financial Officer, will host a company presentation at 2:15 pm ET and participate in one-on-one meetings throughout the day.
DATE: April 15, 2026TIME: 2:15 pm ET
Investors attending the conference who are interested in scheduling a meeting with management can do so by contacting their Needham representative, or by emailing ECOR Investor Relations at investors@electrocore.com.

About electroCore, Inc.

electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visitwww.electrocore.com.

Contact:ECOR Investor Relations(973) 302-9253investors@electrocore.com

Frequently Asked Questions

When is electroCore's presentation at the conference?

electroCore's presentation is scheduled for April 15, 2026, at 2:15 pm ET.

Who will represent electroCore at the conference?

Joshua Lev, Interim President and CFO, will represent electroCore.

How can investors schedule a meeting with electroCore's management?

Investors can schedule meetings by contacting their Needham representative or emailing ECOR Investor Relations.

What products does electroCore offer?

electroCore offers gammaCore® and Quell® for chronic pain, along with wellness products like Truvaga™.

Last updated: Apr 8, 2026